Secretin for refractory schizophrenia

Schizophrenia Research

Volumn 66, Issue 2-3, 2004, Pages 177-181

  Sheitman, Brian B ^a,b   Knable, Michael B ^c   Jarskog, L Fredrik ^a,b   Chakos, Miranda ^a,b   Boyce, Leslie H ^b   Early, John ^a,d   Lieberman, Jeffrey A ^a,b  

^a Dorothea Dix Hospital   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Stanley Medical Research Institute   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Autism; Schizophrenia; Secretin

Indexed keywords

GASTROINTESTINAL POLYPEPTIDE; PLACEBO; SECRETIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG INDICATION; FEMALE; HUMAN; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZATION; RATING SCALE; SCHIZOPHRENIA; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

EID: 0346876282     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(03)00068-9     Document Type: Article

References (16)

1. Bachus S.E., Hyde T.M., Herman M.H., Egan M.F., Kleinman J.E. Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. J. Psychiatr. Res. 31:1997;233-256.
2. Coniglio S.J., Lewis J.D., Lang C., Burns T.G., Subhani-Siddique R., Weintraub A., Schub H., Holden E.W. J. Pediatr. 138:2001;649-655.
3. DeLecea L., Kilduff T.S., Peyron C., Gao X.-B., Foye P.E., Danielson P.E., Fukuhara C., Battenberg E.L.F., Glautvik V.T., Bartlett F.S., Frankel W.N., van den Pol A.N., Bloom F.E., Gautvik K.M., Sutcliffe J.G. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U. S. A. 95:1998;322-327.
4. Dunn-Geier J., Ho H.H., Auersperg E., Doyle D., Eaves L., Matsuba C., Orrbine E., Pham B., Whiting S. Effect of secretin on children with autism: a randomized controlled trial. Dev. Med. Child Neurol. 42:2000;796-802.
5. Gabriel S.M., Davidson M., Haroutunian V., Powchik P., Bierer L.M., Purohit D.P., Perl D.P., Davis K.L. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol. Psychiatry. 39:1996;79-81.
6. Horvath K., Stefanatos G., Sokolski K.N., Wachtel R., Nabors L., Tildon J.T. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J. Assoc. Acad. Minor. Physicians. 9:1998;9-15.
7. Lahti R.A., Cochrane E.V., Roberts R.C., Conley R.R., Tamminga C.A. 3H-Neurotensin receptor densities in human postmortem brain tissue obtained from normal and schizophrenic persons. An autoradiographic study. J. Neural. Transm. 105:1998;507-516.
8. Lightdale J.R., Hayer C., Duer A., Lind-white C., Jenkins S., Siegel B., Elliot G.R., Heyman M.B. Effects of intravenous secretin on language and behavior of children with autism and gastrointestinal symptoms: a single-blinded, open-label study. Pediatrics. 108:2001;90.
9. Moroji T., Watanabe N., Aoki N., Itoh S. Antipsychotic effects of ceruletide (caerulein) on chronic schizophrenia. Arch. Gen. Psychiatry, Apr. 39(4):1982;485-486.
10. Nair N.P.V., Bloom D.M., Nestoros J.N., Schwartz G. Therapeutic efficacy of cholecystokinin in neuroleptic-resistant schizophrenic subjects. Psychopharmacol. Bull. 19:1983;134-136.
11. Owley T., McMahon W., Cook E.H., Laulhere T., South M., Mays L.Z., Shernoff E.S., Lainhart J., Modahl C.B., Corsello C., Ozonoff S., Risi S., Lord C., Leventhal B.L., Filipek P.A. Multisite, double-blind, placebo-controlled trial of porcine secretin in autism. J. Am. Acad. Child Adolesc. Psych. 40:2001;1293-1299.
12. Roberts W., Weaver L., Brian J., Bryon S., Emelianova S., Griffiths A.M., MacKinnon B., Yim C., Wolpin J., Koren G. Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial. Pediatrics. 107:2001;E71.
13. Sandler A.D., Sutton K.A., DeWeese J., Girardi M.A., Sheppard V., Bodfish J.W. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N. Engl. J. Med. 341:1999;1801-1806.
14. Siegel J.M. Narcolepsy: a key role for hypocretins (orexins). Cell. 98:1999;409-412.
15. Tooney P.A., Crawter V.C., Chahl L.A. Increased tachykinin NK(1) receptor immunoreactivity in the prefrontal cortex in schizophrenia. Biol. Psychiatry. 49:2001;523-527.
16. Zachrisson O., de Belleroche J., Wendt K.R., Hirsch S., Lindefors N. Cholecystokinin B receptor mRNA isoforms: expression in schizophrenic brains. NeuroReport. 10:1999;3265-3268.